| Breast Cancer | ||||||
| No. | Study Title | Principle Investigator | Sponsor | Type | Recruiting | Study status |
| 1 | APPALACHES study: A Phase II study of Adjuvant PALbociclib as an Alternative to CHemotherapy in Elderly patientS with high-risk ER+/HER2- early breast cancer. | Dr. Hikmat Abdel-Razeq | EORTC | Clinical Trial | Yes | Ongoing |
| 2 | ICRG 1021 study: Multicentre, International neoadjuvant randomized double-blind trial comparing Fulvestrant® to a combination of Fulvestrant® and Palbociclib (CDK 4/6 Inhibitor) in patients with operable luminal breast cancer responding to Fulvestrant. | Dr. Hikmat Abdel-Razeq | ICRG | Clinical Trial | Yes | Ongoing |
| 3 | AMALEE (Ribo 400/600) study: A phase II, multicenter, randomized, open-label study to evaluate the safety and efficacy of 400 mg of ribociclib in combination with non-steroidal aromatase inhibitors for the treatment of pre- and postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer who received no prior therapy for advanced disease. | Dr. Hikmat Abdel-Razeq | Novartis | Clinical Trial | Yes | Ongoing |
| 4 | Right Choice study: A phase II randomized study of the combination of Ribociclib plus goserelin acetate with Hormonal Therapy versus physician choice chemotherapy in premenopausal or perimenopausal patients with hormone receptor- positive/HER2-negative inoperable locally advanced or metastatic breast cancer. | Dr. Hikmat Abdel-Razeq | Novartis | Clinical Trial | Yes | Ongoing |
| 5 | PhranceSCa study: A randomized, multicenter, open-label Cross-over study to evaluate patient Preference and satisfaction of Subcutaneous administration of the Fixed-dose combination of pertuzumab And trastuzumab in patients with HER2positive Early Breast Cancer. | Dr. Hikmat Abdel-Razeq | Roche | Clinical Trial | No | Ongoing |
| 6 | MONALEESA-3 Study: A randomized double-blind, placebo controlled Study of ribociclib in combination with fulvestrant for the treatment of men and postmenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer who have received no or only one line of prior endocrine treatment. | Dr. Hikmat Abdel-Razeq | Novartis | Clinical Trial | No | Ongoing |
| 7 | COMPLEEMENT-1 study: An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease. | Dr. Hikmat Abdel-Razeq | Novartis | Clinical Trial | No | Ongoing |
| 8 | TRIPOLI study: Triple Negative Breast Cancer Prospective Registry in Middle East and Africa. | Dr. Hikmat Abdel-Razeq | Merck | Registry Study | No | Ongoing |
| 9 | PIK3CA Registry - A descriptive study of PIK3CA mutations in patients with HR+/Her2- advanced breast cancer. | Dr. Hikmat Abdel-Razeq | Novartis | Registry Study | Pending | Ongoing |
| 10 | A tattoo or a clip? A study to compare between applying a tattoo or a clip to axillary lymph nodes in breast cancer patients who undergo SLNBx. A prospective, double blind and randomized pilot study. | KHCC | Clinical Trial | No | On-going | |